间充质干细胞疗法治疗急性呼吸窘迫综合征的前景。
The promise of mesenchymal stem cell therapy for acute respiratory distress syndrome.
作者信息
Antebi Ben, Mohammadipoor Arezoo, Batchinsky Andriy I, Cancio Leopoldo C
机构信息
From the United States Army Institute of Surgical Research (B.A., A.M., A.I.B., L.C.C.), San Antonio, Texas; Oak Ridge Institute for Science and Education (A.M.), Oak Ridge, TN; and The Geneva Foundation (A.I.B.), Tacoma, Washington.
出版信息
J Trauma Acute Care Surg. 2018 Jan;84(1):183-191. doi: 10.1097/TA.0000000000001713.
This review describes the current state of the science on mesenchymal stem cell (MSC) treatment for acute lung injury (ALI). The general characteristics, regenerative potential, and mechanism of action of MSCs are first presented. Next, particular emphasis is placed on the application of MSCs for the treatment of acute respiratory distress syndrome (ARDS) in preclinical and clinical studies. Finally, we discuss current challenges and future directions in the field presented from a clinician-researcher perspective. The objective of this work is to provide the readership with a current review of the literature discussing the hurdles and overall promise of MSCs as therapeutic interventions for the treatment of ARDS.
本综述描述了间充质干细胞（MSC）治疗急性肺损伤（ALI）的科学现状。首先介绍了MSC的一般特征、再生潜力和作用机制。接下来，重点阐述了MSC在临床前和临床研究中治疗急性呼吸窘迫综合征（ARDS）的应用。最后，我们从临床研究人员的角度讨论了该领域当前面临的挑战和未来方向。这项工作的目的是为读者提供一篇当前文献综述，讨论MSC作为治疗ARDS的治疗干预措施所面临的障碍和总体前景。
Zotero 插件